PLA2G7 ELISA Kit

Catalog No. ABIN414412

Human PLA2G7 ELISA Kit, Colorimetric assay for quantification of Human PLA2G7, that has been mentioned in 13+ publications.

Quick Overview for PLA2G7 ELISA Kit (ABIN414412)

Target: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 0.625 ng/mL - 40 ng/mL

Application: ELISA

Sample Type: Plasma, Serum

Product Details PLA2G7 ELISA Kit

Minimum Detection Limit: 0.625 ng/mL

Purpose: The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of LpPLA2 in Serum,Plasma,Biological Fluids

Analytical Method: Quantitative

Specificity:

This assay has high sensitivity and excellent specificity for detection of Phospholipase A2 Group VII (LpPLA2).
No significant cross-reactivity or interference between Phospholipase A2 Group VII (LpPLA2) and analogues was observed.

Cross-Reactivity (Details): No significant cross-reactivity or interference between Phospholipase A2, Lipoprotein Associated (LpPLA2) and analogues was observed.

Sensitivity: < 0.255 ng/mL

Components:

• Pre-coated, 96-well strip plate
• Plate sealer
• Standard
• Standard Diluent
• Detection Reagent A
• Assay Diluent A
• Detection Reagent B
• Assay Diluent B
• TMB Substrate
• Stop Solution
• Wash Buffer (30X)
• Instruction manual

Material not included:

• Microplate reader with 450 nm filter.
• Precision single or multi-channel pipettes and disposable tips.
• Eppendorf Tubes for diluting samples.
• Deionized or distilled water.
• Absorbent paper for blotting the microtiter plate.
• Container for Wash Solution

Application Details

Application Notes:

• Limited by the current condition and scientific technology, we cannot completely conduct the comprehensive identification and analysis on the raw material provided by suppliers. So there might be some qualitative and technical risks to use the kit.
• The final experimental results will be closely related to validity of the products, operation skills of the end users and the experimental environments. Please make sure that sufficient samples are available.
• Kits from different batches may be a little different in detection range, sensitivity and color developing time.
• Do not mix or substitute reagents from one kit lot to another. Use only the reagents supplied by manufacturer.
• Protect all reagents from strong light during storage and incubation. All the bottle caps of reagents should be covered tightly to prevent the evaporation and contamination of microorganism.
• There may be some foggy substance in the wells when the plate is opened at the first time. It will not have any effect on the final assay results. Do not remove microtiter plate from the storage bag until needed.
• Wrong operations during the reagents preparation and loading, as well as incorrect parameter setting for the plate reader may lead to incorrect results. A microplate plate reader with a bandwidth of 10nm or less and an optical density range of 0-3 O.D. or greater at 450 ± 10nm wavelength is acceptable for use in absorbance measurement. Please read the instruction carefully and adjust the instrument prior to the experiment.
• Even the same operator might get different results in two separate experiments. In order to get better reproducible results, the operation of every step in the assay should be controlled. Furthermore, a preliminary experiment before assay for each batch is recommended.
• Each kit has been strictly passed Q.C test. However, results from end users might be inconsistent with our in-house data due to some unexpected transportation conditions or different lab equipments. Intra-assay variance among kits from different batches might arise from above factors, too.
• Kits from different manufacturers for the same item might produce different results, since we have not compared our products with other manufacturers.

Comment:

Information on standard material:
The standard might be recombinant protein or natural protein, that will depend on the specific kit. Moreover, the expression system is E.coli or yeast or mammal cell. There is 0.05% proclin 300 in the standard as preservative.

Information on reagents:
The stop solution used in the kit is sulfuric acid with concentration of 1 mol/L. And the wash solution is TBS. The standard diluent contains 0.02 % sodium azide, assay diluent A and assay diluent B contain 0.01% sodium azide. Some kits can contain is BSA in them.

Information on antibodies:
The provided antibodies and their host vary in different kits.

Sample Volume: 100 μL

Assay Time: 3 h

Plate: Pre-coated

Protocol: 1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 2 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

Assay Precision:

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Restrictions: For Research Use only

Handling

Precaution of Use: The Stop Solution suggested for use with this kit is an acid solution. Wear eye, hand, face, and clothing protection when using this material.

Handling Advice: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5 % within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Storage: 4 °C

Storage Comment:

• For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20°C upon receipt while the others should be at 4°C.
• For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal.
  Note: It is highly recommended to use the remaining reagents within 1 month provided this is within the expiration date of the kit.
• For ELISA kit, 1 day storage at 37°C can be considered as 2 months at 4°C, which means 3 days at 37°C equaling 6 months at 4°C.

Expiry Date: 6 months

References for PLA2G7 ELISA Kit (ABIN414412)

Tsai, Wu, Tseng, Leu, Yin, Lin, Chang, Wang, Yeh, Wu, Chen: "Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions." in: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 120, Issue 1 Pt 3, pp. 728-736, (2021) (PubMed).

El Messaoudi, Wouters, van Swieten, Pickkers, Noyez, Kievit, Abbink, Rasing-Hoogveld, Bouw, Peters, Coenen, Donders, Riksen, Rongen: "Effect of dipyridamole on myocardial reperfusion injury: A double-blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery." in: Clinical pharmacology and therapeutics, Vol. 99, Issue 4, pp. 381-9, (2016) (PubMed).

Shabalina, Liapina, Rochev, Kostyreva, Tanashian, Suslina: "[In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood]." in: Izvestiia Akademii nauk. Seriia biologicheskaia / Rossi?skaia akademiia nauk, Issue 1, pp. 85-9, (2015) (PubMed).

Yadav, Liu, Kwok, Hama, France, Eatough, Pemberton, Schofield, Siahmansur, Malik, Ammori, Issa, Younis, Donn, Stevens, Durrington, Soran: "Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients." in: Journal of the American Heart Association, Vol. 4, Issue 9, pp. e001508, (2015) (PubMed).

Fortunato, Bláha, Bis, Štásek, Andrýs, Vojá?ek, Jurašková, Sobotka, Polanský, Brtko: "Lipoprotein-associated phospholipase A? mass level is increased in elderly subjects with type 2 diabetes mellitus." in: Journal of diabetes research, Vol. 2014, pp. 278063, (2014) (PubMed).

Mai, Wang, Wen, Lin, Niu: "Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus." in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, Vol. 30, Issue 3, pp. 241-4, (2014) (PubMed).

Tremblay, Lamarche, Deacon, Weisnagel, Couture: "Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes." in: Metabolism: clinical and experimental, Vol. 63, Issue 9, pp. 1141-8, (2014) (PubMed).

Gouni-Berthold, Berthold, Huh, Berman, Spenrath, Krone, Mantzoros: "Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo." in: PLoS ONE, Vol. 8, Issue 9, pp. e72858, (2013) (PubMed).

Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: "Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients." in: Atherosclerosis, Vol. 230, Issue 1, pp. 164-70, (2013) (PubMed).

Enseleit, Sudano, Périat, Winnik, Wolfrum, Flammer, Fröhlich, Kaiser, Hirt, Haile, Krasniqi, Matter, Uhlenhut, Högger, Neidhart, Lüscher, Ruschitzka, Noll: "Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study." in: European heart journal, Vol. 33, Issue 13, pp. 1589-97, (2012) (PubMed).

Colak, Senates, Ozturk, Doganay, Coskunpinar, Oltulu, Eren, Sahin, Ozkanli, Enc, Ulasoglu, Tuncer: "Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease." in: Metabolic syndrome and related disorders, Vol. 10, Issue 2, pp. 103-9, (2012) (PubMed).

Schaefer, McNamara, Asztalos, Tayler, Daly, Gleason, Seman, Ferrari, Rubenstein: "Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects." in: The American journal of cardiology, Vol. 95, Issue 9, pp. 1025-32, (2005) (PubMed).

Savoiardo: "The vascular territories of the carotid and vertebrobasilar systems. Diagrams based on CT studies of infarcts." in: Italian journal of neurological sciences, Vol. 7, Issue 4, pp. 405-9, (1986) (PubMed).

Target Details for PLA2G7

Target: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Alternative Name: LpPLA2

Background: PLA2G7, PAF-AH, PAFAH, Lp-PLA2, LDL-PLA2, Platelet Activating Factor Acetylhydrolase,Plasma, Phospholipase A2,Group VII, LDL-associated phospholipase A2, Phospholipase A2, Lipoprotein Associated

UniProt: Q13093

Pathways: Peptide Hormone Metabolism